# Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers

> **NCT03826719** · PHASE1,PHASE2 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** NBP607QIV
- **BIOLOGICAL:** Agrippal

## Key facts

- **NCT ID:** NCT03826719
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-17
- **Primary completion:** 2014-03-28
- **Final completion:** 2014-03-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03826719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03826719, "Safety, Tolerability and Immunogenicity of NBP607QIV in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03826719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*